title: Bladder cancer: Always consider extravesical sites when BCG fails.
authors.affiliation: Scott Department of Urology, Baylor College of Medicine, 7200 Cambridge Street, MC BCM380, Houston, TX 77030, USA.
authors.forename: Friedrich-Carl
authors.initials: FC
authors.lastname: von Rundstedt
authors.affiliation: Scott Department of Urology, Baylor College of Medicine, 7200 Cambridge Street, MC BCM380, Houston, TX 77030, USA.
authors.forename: Seth P
authors.initials: SP
authors.lastname: Lerner
mesh_terms: D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D001500:BCG Vaccine / Q000627:therapeutic use*; D002295:Carcinoma, Transitional Cell / Q000175:diagnosis* / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007680:Kidney Neoplasms / Q000175:diagnosis*; D008297:Male; D014523:Urethral Neoplasms / Q000175:diagnosis*; D001749:Urinary Bladder Neoplasms / Q000188:drug therapy*
chemical_list: D000276:Adjuvants, Immunologic; D001500:BCG Vaccine